<DOC>
	<DOC>NCT00745433</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to investigate the efficacy (e.g. glycemic control) and safety (e.g. hypoglycemic episodes) when adding repaglinide to a monotherapy of metformin in type 2 diabetic patients under normal clinical practice</brief_summary>
	<brief_title>Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes Metformin monotreatment HbA1c greater than 7% Treatment according to SPC Informed consent obtained Any contraindication to the use of repaglinide (according to the SPC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>